Extended Data Fig. 1: Transmembrane-anchored MERS-CoV S-2P (S-2P_TM) mRNA elicits more potent pseudovirus neutralizing antibody responses than secreted MERS-CoV S(2P) and S WT mRNA.
From: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
a, b, C57BL/6J mice (n = 10/group) were immunized at weeks 0 and 4 with (a) 0.4, 2, or 10 μg of MERS-CoV S-2P_TM (red) or MERS S-2P_secreted (red hashed) or (b) 0.016 μg, 0.08 μg, or 0.4 μg of MERS-CoV S(2P) or MERS-CoV S WT_TM (black) mRNA. Sera were collected 4 weeks post-boost and assessed for neutralizing antibodies against MERS-CoV m35c4 pseudovirus. Immunogens were compared at each dose level by two-sided Mann–Whitney U-test. *P < 0.05, ****P < 0.0001. Data are presented as GMT ± geometric s.d.
